Other
Remission
0
Pipeline Programs↗
7
Active Trials↗
6
Companies Involved↗
Remission is an early-stage landscape with 0 programs across 6 companies. The most active players are Pfizer, Johnson & Johnson Taiwan Ltd, UCB.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
37
clinical trials
Completed20 · 54%
Unknown status7 · 19%
Active, not recruiting4 · 11%
Terminated3 · 8%
Not yet recruiting2 · 5%
Recruiting1 · 3%
Clinical Trials
Trial Activity
37 trials
Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib
Recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT05095649·15 enrolled
Risankizumab Long-term Remission Study
Active, not recruiting·—·Phase 4·NCT04630652·20 enrolled
Remission Through Early Monitored Insulin Therapy - Duration Month
Completed·—·Phase 4·NCT03670641·10 enrolled
COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA
Completed·—·Phase 4·NCT03649061·276 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)